Kotelevets SM. Risks of anti-Helicobacter therapy and long-term therapy with antisecretory drugs. World J Gastroenterol 2025; 31(4): 101933 [DOI: 10.3748/wjg.v31.i4.101933]
Corresponding Author of This Article
Sergey M Kotelevets, MD, Department of Therapy, North Caucasus State Academy, 75/32 Lenina Street, Cherkessk 369000, Russia. smkotelevets@mail.ru
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Jan 28, 2025; 31(4): 101933 Published online Jan 28, 2025. doi: 10.3748/wjg.v31.i4.101933
Risks of anti-Helicobacter therapy and long-term therapy with antisecretory drugs
Sergey M Kotelevets
Sergey M Kotelevets, Department of Therapy, North Caucasus State Academy, Cherkessk 369000, Russia
Author contributions: Kotelevets SM designed the overall concept and outline of the manuscript, wrote and edited the manuscript, and reviewed literatures.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Sergey M Kotelevets, MD, Department of Therapy, North Caucasus State Academy, 75/32 Lenina Street, Cherkessk 369000, Russia. smkotelevets@mail.ru
Received: October 1, 2024 Revised: November 8, 2024 Accepted: December 6, 2024 Published online: January 28, 2025 Processing time: 89 Days and 18.3 Hours
Core Tip
Core Tip: Helicobacter pylori (H. pylori) infection has a protective effect on gastroesophageal reflux disease. Both of these diseases have a very high incidence and prevalence. The main obstacle to effective treatment H. pylori infection and gastroesophageal reflux disease is the possible side effects after use of proton pump inhibitors (PPIs). The article provides a precise analysis of scientific reviews and meta-analyses, as well as experimental scientific morphological studies on this topic. The author presented his original field of vision. He convincingly substantiated his opinion, proposed to interpret possible morphological and functional changes in the gastric mucosa after long-term use of PPIs as compensatory mechanisms of sanogenesis. This field of view will increase the number of indications for the use of PPIs and other antisecretory drugs.
